In these seven patients, three PRs (two with FGFR2 fusion-positive iCCA and one with urothelial cancer with FGFR2 and FGF19 amplification) and two durable SDs with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed. This evidence concerns the gene FGF19 and adrenal cortex carcinoma.